
Vildagliptin (50mg) + Metformin (500mg)
Active composition
+1 more active ingredient
Vildagliptin inhibits DPP-4, leading to increased levels of incretin hormones, which stimulate insulin secretion and decrease glucagon levels.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Insuvil-M Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, which increase insulin secretion and suppress glucagon release in a glucose-dependent manner. The synergistic action of these agents helps achieve better glycemic control compared to monotherapy, reducing fasting and postprandial blood glucose levels. Insuvil-M is prescribed as an adjunct to diet and exercise when these measures alone do not provide adequate glycemic control. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and rarely, hypoglycemia when combined with other antidiabetic agents. Regular monitoring of renal function and blood glucose levels is recommended during therapy. Insuvil-M should be used under medical supervision with appropriate lifestyle modifications to optimize therapeutic outcomes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Insuvil-M Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Medical Advice
Insuvil-M Tablet should be used with caution in patients with kidney disease. Dose adjustment of Insuvil-M Tablet may be needed. Please consult your doctor.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
Insuvil-M Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Insuvil-M Tablet

Metformin (500mg) + Vildagliptin (50mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Vildagliptin inhibits DPP-4, leading to increased levels of incretin hormones, which stimulate insulin secretion and decrease glucagon levels.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Insuvil-M Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, which increase insulin secretion and suppress glucagon release in a glucose-dependent manner. The synergistic action of these agents helps achieve better glycemic control compared to monotherapy, reducing fasting and postprandial blood glucose levels. Insuvil-M is prescribed as an adjunct to diet and exercise when these measures alone do not provide adequate glycemic control. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and rarely, hypoglycemia when combined with other antidiabetic agents. Regular monitoring of renal function and blood glucose levels is recommended during therapy. Insuvil-M should be used under medical supervision with appropriate lifestyle modifications to optimize therapeutic outcomes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Insuvil-M Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Medical Advice
Insuvil-M Tablet should be used with caution in patients with kidney disease. Dose adjustment of Insuvil-M Tablet may be needed. Please consult your doctor.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
Insuvil-M Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Insuvil-M Tablet













